EFMC-ACSMEDI MedChem Frontiers 2019

Joint Symposium on Medicinal Chemistry Frontiers

 Krakow, Poland    June 10-13, 2019

Plenary Speakers

First Time Disclosure
The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders (IL09)

Dr Yves P. AUBERSON
Dr Yves P. AUBERSON
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland
Read more

Derivatives of 1,3,5-triazine as a New Trend in the Search for the 5-HT6 Receptor Ligands with Therapeutic Perspectives (PL01)

Dr Jadwiga HANDZLIK
Dr Jadwiga HANDZLIK
MEDICAL COLLEGE OF JAGIELLONIAN UNIVERSITY, Krakow, Poland
Read more

Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders (PL02)

Prof. Krzysztof  PALCZEWSKI
Prof. Krzysztof PALCZEWSKI
CASE WESTERN RESERVE UNIVERSITY, Cleveland, United States
Read more

Next Generation Pain Therapeutics for the Opioid Crisis: Design of Bifunctional Nociceptin/Mu Opioid GPCR Ligands as non-Addicting Analgesics (PL03)

Dr Nurulain ZAVERI
Dr Nurulain ZAVERI
ASTRAEA THERAPEUTICS, Mountain View, United States
Read more

Matrix Metallo-Proteinases

Libraries of Fluorogenic Substrates with Natural and Unnatural Amino Acids as a Tool in Design of Active and Specific Probes for Investigation of Proteolytic Enzymes (IL01)

Prof. Marcin DRAG
Prof. Marcin DRAG
WROCLAV UNIVERSITY OF TECHNOLOGY, Wroclaw, Poland
Read more

MMP-9 at the Synapse in the Brain and Mind (IL02)

Prof. Leszek KACZMAREK
Prof. Leszek KACZMAREK
NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY, Warsaw, Poland
Read more

Metalloproteinase Cleavage Control of Interferon Alpha and Gamma Dampens Inflammation and Anti-Viral Immunity (IL03)

Prof. Christopher OVERALL
Prof. Christopher OVERALL
UNIVERSITY OF BRITISH COLUMBIA, Vancouver, Canada
Read more

Chemical Biology Tools & Target Engagement Technologies

Protein-Ligand Interactions: How Medicinal Chemistry Contributes to the Understanding of Molecular Recognition (IL17)

Dr Marc NAZARE
Dr Marc NAZARE
FMP, Berlin, Germany
Read more

Adventures in Targeting Protein Lipdation: Breaking Drug Resistance Using Fragment Deconstruction and Chemical Biology (IL18)

Prof. Edward TATE
Prof. Edward TATE
IMPERIAL COLLEGE LONDON, London, United Kingdom
Read more

Tankyrase Inhibitors : Evidence for Therapeutic Potential in Immuno-Oncology

Dr Luc VAN HIJFTE
Dr Luc VAN HIJFTE
SCT & MERCACHEM-SYNCOM, Nijmegen, The Netherlands

GPCRs: a Discovery Powerhouse

Design of Orexin 1 Receptor Selective Antagonists (IL11)

Dr Uta LESSEL
Dr Uta LESSEL
BOEHRINGER INGELHEIM, Biberach an der Riss, Germany
Read more

Next Generation GPR119 Agonists as Potential Treatment for Cardiometabolic Diseases (IL12)

Dr Lothar SCHWINK
Dr Lothar SCHWINK
SANOFI, Frankfurt Am Main, Germany
Read more

G Protein-Coupled Receptors: the Structural Basis for their Pharmacology (IL10)

Dr Chris TATE
Dr Chris TATE
MRC LABORATORY OF MOLECULAR BIOLOGY, Cambridge, United Kingdom
Read more

Genomics in Drug Discovery : Roles for Chemistry

Designing Synthetic Gene Regulators (SynGR) (IL04)

Prof. Aseem ANSARI
Prof. Aseem ANSARI
UNIVERSITY OF WISCONSIN-MADISON, Madison, United States
Read more

Exploring Bacterial Genomes for Natural Product Discovery and Development (IL05)

Prof. Alessandra S.  EUSTAQUIO
Prof. Alessandra S. EUSTAQUIO
UNIVERSITY OF ILLINOIS AT CHICAGO, Chicago, United States
Read more

Integrative Screening Identifies a Novel Node in the Oncogenic YAP/HIPPO Pathway (IL06)

Dr Mathias FREDERIKSEN
Dr Mathias FREDERIKSEN
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (NIBR), Basel, Switzerland

Specific and Multi-Targeted Drugs

Charting New Paths in Multi-Target Drug Discovery for Alzheimer’s Disease (IL13)

Prof. Maria Laura BOLOGNESI
Prof. Maria Laura BOLOGNESI
UNIVERSITY OF BOLOGNA, Bologna, Italy
Read more

Chemical Biology for Drug Discovery: A Click and Play Approach Exemplified by ERK1/2 Probes (OC03)

Dr Charlotte GRIFFITHS-JONES
Dr Charlotte GRIFFITHS-JONES
ASTEX PHARMACEUTICALS, Cambridge, United Kingdom
Read more

Identification and in-vivo Efficacy Studies of a Nicotinamide Derivative as Novel NNMT Inhibitor (OC04)

Dr Sven RUF
Dr Sven RUF
SANOFI-AVENTIS DEUTSCHLAND GMBH, Frankfurt am Main, Germany
Read more

Multiple Targeting - The Histamine H3 Receptor Pharmacophore as Central Element (IL14)

Prof. Holger STARK
Prof. Holger STARK
HEINRICH HEINE UNIVERSITY DÜSSELDORF, Duesseldorf, Germany
Read more

Targeted Covalent Inhibitors

Mining the Protein Kinase Cysteinome (IL22)

Dr Tjeerd BARF
Dr Tjeerd BARF
ACERTA PHARMA BV, Oss, The Netherlands
Read more

Safety First: Covalent Inhibitors from a Safety Perspective (IL20)

Dr Mickael MOGEMARK
Dr Mickael MOGEMARK
ASTRAZENECA, Mölndal, Sweden
Read more

Adventures in Functional Assignment and Inhibition of Metallo-Enzymes (IL21)

Prof. Christopher J. SCHOFIELD
Prof. Christopher J. SCHOFIELD
UNIVERSITY OF OXFORD, Oxford, United Kingdom
Read more

Adding AI to the Drug Discovery Tool Box

Capturing and Applying Knowledge to Guide Compound Optimisation (OC10)

Mr Nick FOSTER
Mr Nick FOSTER
OPTIBRIUM, Cambridge, United Kingdom
Read more

Learning the Art of Chemical Synthesis with Deep Neural Networks and Discipline Scale Data (IL23)

Prof. Mark WALLER
Prof. Mark WALLER
UNIVERSITY OF WOLLONGONG, Wollongong, Australia
Read more

Applications of Artificial Intelligence in Drug Discovery – Separating Hype From Utility (IL24)

Dr Pat WALTERS
Dr Pat WALTERS
RELAY THERAPEUTICS, Cambridge, United States
Read more

Augmented Intelligence for Compound Design (OC09)

Dr Michal WARCHOL
Dr Michal WARCHOL
ARDIGEN, Krakow, Poland
Read more

Advances in Protein Degradation Technologies

Targeted Protein Degradation with Small Molecules: how PROTACs Work (IL07)

Prof. Alessio CIULLI
Prof. Alessio CIULLI
UNIVERSITY OF DUNDEE, Dundee, United Kingdom
Read more

Drugging Challenging E3 Ligases: A Novel Multidisciplinary Approach to Identify Small-Molecules that Bind FBW7 (OC02)

Ms Miriam MARTINEZ CARTRO
Ms Miriam MARTINEZ CARTRO
UNIVERSITY OF BARCELONA, Barcelona, Spain
Read more

The Ubiquitin System (IL08)

Prof. Huib OVAA
Prof. Huib OVAA
LEIDEN UNIVERSITY MEDICAL CENTER, Leiden, The Netherlands
Read more

Small-Molecule Modulation of Cereblon Protein Level (OC01)

Mr Christian STEINEBACH
Mr Christian STEINEBACH
UNIVERSITY OF BONN, Bonn, Germany
Read more

Opioid, Pain, Endo-Cannabinoid

The Discovery and Development of the Clinical FAAH Inhibitor JNJ-42165279 (OC06)

Prof. James BREITENBUCHER
Prof. James BREITENBUCHER
UNIVERSITY OF CALIFORNIA SAN FRANCISCO, San Francisco, United States
Read more

Potential of Natural Cannabinoids and Synthetic Cannabinoids in Neuroprotection (IL16)

Prof. Rafael FRANCO
Prof. Rafael FRANCO
UNIVERSITY OF BARCELONA, Barcelona, Spain
Read more

Cannabinoid Receptor Type 2 Modulation to Improve Outcomes for Cartilage Repair in the Osteoarthritic Joint (IL15)

Prof. Katarzyna STAROWICZ-BUBAK
Prof. Katarzyna STAROWICZ-BUBAK
INSTITUTE OF PHARMACOLOGY, POLISH ACADEMY OF SCIENCES, Krakow, Poland
Read more

Discovery of Best in-class, Novel, Selective, Potent and Peripheral FLT3 Inhibitors, a New Way to Treat Neuropathic Pain (OC05)

Dr Dominique SURLERAUX
Dr Dominique SURLERAUX
BCI PHARMA, Liège, Belgium
Read more

Pharma Research Highlights in Poland

Discovery of OAT-2068 - A Potent, Selective, Orally Bioavailable Inhibitor of Mouse Chitotriosidase and its In Vivo Activity in the Bleomycin-Induced Pulmonary Fibrosis Model in Mice (OC07)

Dr Agnieszka BARTOSZEWICZ
Dr Agnieszka BARTOSZEWICZ
ONCOARENDI THERAPEUTICS SA, Warszawa, Poland
Read more

DPD-inspired Small Heterocyclic Libraries Characterized as Novel LsrK Kinase Inhibitors: an Opportunity to Fight Antimicrobial Resistance (OC08)

Dr Anna KARAWAJCZYK
Dr Anna KARAWAJCZYK
SELVITA, Krakow, Poland